Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-targeted inhibitors

被引:31
作者
Chen, Calvin Yu-Chian [1 ,2 ]
机构
[1] China Med Univ, Sch Chinese Med, Lab Computat & Syst Biol, Taichung 40402, Taiwan
[2] Asia Univ, Dept Bioinformat, Taichung 41354, Taiwan
关键词
Dual-targeted inhibitors; HER2; HSP90; CoMFA; Pharmacophore; DE-NOVO DESIGN; TYROSINE KINASE; PHARMACOINFORMATICS APPROACH; COX-2; INHIBITORS; RECEPTOR; BINDING; CANCER; COMFA; DERIVATIVES; DISCOVERY;
D O I
10.1016/j.jtice.2009.08.007
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
Heat shock protein 90 (HSP90) and human epidermal growth factor receptor 2 protein (HER2) are involved in several signal pathways for cancer cell proliferation. I focused on these two hallmarkers to design the dual-targeted inhibitors for cancer therapy. The comparative molecular field analysis (CoMFA) and pharmacophore analysis were employed for generating the predictive models. According the leave-one out (LOO) cross-validation, the CoMFA models obtained the significant r(2) values of 0.986 and 0.982 for HSP90 and HER2, respectively. The contour maps of both targets indicated that there were amount of similar bulky favors area. Besides, the cost difference of pharmacophore models was 48.539 for 70% correlation with the experiment. At the C2 position of the benzene ring, the HER2 model was more favor of steric bulky than HSP90. Contrast to HER2 model, the room which is near pent-4-ynyl group was more favor of steric bulky for HSP90 model. This study provided the significant CoMFA models and pharmacophore features for designing the HER2/HSP90 dual-targeted inhibitors. (C) 2009 Published by Elsevier B.V. on behalf of Taiwan Institute of Chemical Engineers.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 35 条
[21]   Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors [J].
Holden, SN ;
Eckhardt, SG ;
Basser, R ;
de Boer, R ;
Rischin, D ;
Green, M ;
Rosenthal, MA ;
Wheeler, C ;
Barge, A ;
Hurwitz, HI .
ANNALS OF ONCOLOGY, 2005, 16 (08) :1391-1397
[22]   Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors [J].
Immormino, Robert M. ;
Kang, Yanlong ;
Chiosis, Gabriela ;
Gewirth, Daniel T. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (16) :4953-4960
[23]   Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer [J].
Kindler, HL ;
Friberg, G ;
Skoog, L ;
Wade-Oliver, K ;
Vokes, EE .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (04) :340-344
[24]   Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90 [J].
Llauger, L ;
He, HZ ;
Kim, J ;
Aguirre, J ;
Rosen, N ;
Peters, U ;
Davies, P ;
Chiosis, G .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (08) :2892-2905
[25]   CoMFA based de novo design of pyridazine analogs as PTP1B inhibitors [J].
Nair, Pramod C. ;
Sobhia, M. Elizabeth .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2007, 26 (01) :117-123
[26]   Heat shock protein 90: the cancer chaperone [J].
Neckers, Len .
JOURNAL OF BIOSCIENCES, 2007, 32 (03) :517-530
[27]   Epidermal growth factor receptor (EGFR) signaling in cancer [J].
Normanno, N ;
De Luca, A ;
Bianco, C ;
Strizzi, L ;
Mancino, M ;
Maiello, MR ;
Carotenuto, A ;
De Feo, G ;
Caponigro, F ;
Salomon, DS .
GENE, 2006, 366 (01) :2-16
[28]   In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis [J].
Obermann, WMJ ;
Sondermann, H ;
Russo, AA ;
Pavletich, NP ;
Hartl, FU .
JOURNAL OF CELL BIOLOGY, 1998, 143 (04) :901-910
[29]  
Petrelli A, 2008, CURR MED CHEM, V15, P422
[30]   ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity [J].
Ryan, AJ ;
Wedge, SR .
BRITISH JOURNAL OF CANCER, 2005, 92 (Suppl 1) :S6-S13